Objective-Lowering low-density lipoprotein cholesterol (LDL-C) with statins has been demonstrated to slow plaque progression. This antiatherosclerotic effect in patients with minimal LDL-C lowering has not been investigated. Approach and Results-Six hundred forty-seven patients with angiographic coronary artery disease who were commenced on statin therapy underwent serial imaging with intravascular ultrasound. Responders were defined as a percentage reduction in LDL-C of <15%. Disease progression was compared in responders (n=517) and hyporesponders (n=130) 
S
tatins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, a rate-limiting enzyme in the cholesterol biosynthesis pathway. 1 Inhibition of cholesterol biosynthesis causes reduced secretion of apolipoprotein B-containing lipoproteins from the liver and the upregulation of LDL receptor activity, 2 both of which contribute to low-density lipoprotein cholesterol (LDL-C) lowering. Large clinical trials have consistently demonstrated that lowering levels of LDL-C with statins is associated with profound reductions in cardiovascular event rates in the setting of both primary 3, 4 and secondary prevention. 5, 6 In addition, arterial wall imaging studies have highlighted the importance of intensive LDL-C lowering in slowing disease progression. 7, 8 Our previous serial intravascular ultrasound studies have demonstrated that statin-mediated reduction in LDL-C levels slows the rate of atherosclerotic disease progression and may induce coronary atherosclerosis regression if very LDL-C levels are achieved. 9, 10 As a result, LDL-C lowering with statins has become an integral component of therapeutic strategies in the prevention of cardiovascular disease.
Despite the benefits of statin therapy, considerable interindividual variation exists in response to statin therapy, in terms of the degree of LDL-C lowering. Recent studies have reported that some genetic variations contribute to this interindividual variations in clinical efficacy of statin therapy. 11, 12 Although various pharmacogenetic studies have already revealed different genetic profiles in patients with hyporesponse to statin therapy, the prevalence and clinical characteristics of hyporesponders to statin therapy have not been fully characterized. Moreover, although statin-mediated LDL-C lowering results in slowing disease progression, the impact of diminished response to statins on natural history of coronary atherosclerosis has not been elucidated.
Recently, grayscale intravascular ultrasound has been increasingly used in clinical trials and enhanced our understanding of the factors that influence the natural history of atherosclerosis and its response to the use of antiatherosclerotic
Results

Baseline Clinical Characteristics
In the current study, hyporesponders to statin therapy were observed in 20.0% (n=130) of study population. Baseline clinical characteristics were summarized in Table 1 
Risk Factor Control With Therapy
The degree of risk factor control at baseline and follow-up are summarized in Table 3 . Risk factor control at baseline did not differ between the 2 groups, except lower levels of LDL-C (2.5±0. 
Atheroma Progression
Serial changes in measures of atheroma burden are summarized in 
Discussion
Although clinical trials have established that lowering LDL-C levels with statin therapy reduces the risk of cardiovascular events, 4-7 some patients fail to achieve favorable LDL-C control even under this medical therapy. The current study revealed that 20% of patients treated with statin therapy exhibited minimal reduction in LDL-C level. These patients harbored greater atheroma progression and less atheroma regression. Although some individuals do not respond well to statins, the precise mechanisms underlying poor response to a statin are not well understood. One of the speculative mechanisms is the genetic phenotype associated with the efficacy of statin. Pharmacogenetic studies have reported genetic variations at gene loci that affect intestinal cholesterol absorption or cholesterol production. 11, 12 Although some genetic variations might exist in statin hyporesponders, the current study does not evaluate genetic factors related to statin responsiveness.
Another important contributor to the efficacy of statin is drug compliance because poor adherence of statin results in diminished response to the therapy. However, in the current analysis, including 7 intravascular ultrasound clinical trials, study subjects were tightly monitored in trials and their drug compliance rates were observed >90%.
In the current study, statin hyporesponders exhibited greater progression of coronary atherosclerosis. We have already reported that progression rate (change in PAV) is ≈0.2% in subjects without diabetes mellitus (LDL-C=2.4 mmol/L) and 0.7% in subjects with diabetes mellitus (LDL-C=2.4 mmol/L) who were treated with a statin. 18 Compared with these values, progression rate in statin hyporesponders is substantial (change in PAV=1.2%, LDL-C=2.6 mmol/L). Given previous reports on an association between atheroma progression rate and adverse cardiovascular events, 19 the current findings suggest that statin hyporesponder is an important therapeutic target who requires additional antiatherosclerotic therapy to prevent disease progression, as well as future clinical events.
Several mechanisms could be considered to induce rapid disease progression in stain hyporesponders. Statin-mediated LDL-C lowering plays an important role in halting disease progression. Intravascular imaging studies have shown that achieving lower LDL-C level attenuates disease progression or induces plaque regression. 9, 10 In the current study, an increase in LDL-C level (+6.2%) was observed in these patients at follow-up, despite statin use. This lipid profile may result in the rapidly progressive atherosclerotic form in statin hyporesponders.
Another mechanism related to greater disease progression might be their diminished pleiotropic effect. Statin has been demonstrated to lower C-reactive protein (CRP) levels, independent of its effect on LDL-C. 20 Also, this anti-inflammatory effect of a statin has been shown to associate with disease progression. 21 In the current study, statin hyporesponders were more likely to have smaller reduction in CRP levels compared with statin responders (−16.7% versus −33.6%) although this comparison was statistically nonsignificant (P=0.16). This observation might suggest that statin hyporesponders harbor attenuated pleiotropic effects, potentially contributing to their progressive disease substrate. Further investigation will be warranted to elucidate pleiotropic effect in statin hyporesponders.
Greater disease progression in statin hyporesponders with smaller reduction in CRP level, despite statin therapy, might suggest a critical role of inflammation in atherogenesis. We recently demonstrated the contribution of CRP level to disease progression and cardiovascular events in patients treated with potent statin therapy. 22 Another study reported that optimal control of not only LDL-C but also CRP levels is associated with favorable reduction in cardiovascular events under rosuvastatin use. 23 These observations highlight inflammation as an important therapeutic target to achieve further reduction in disease progression and cardiovascular events. On-going clinical trials might elucidate an effective therapeutic strategy modulating inflammation associated with atherosclerosis. 24, 25 Recent studies have suggested that the downregulation of cholesterol synthesis by statin therapy is compensated by a rise in intestinal cholesterol absorption. 26, 27 Tremblay et al 26 reported that the 12-week treatment with 40 mg in patients with dyslipidemia increased plasma campesterol (+65%) and sitosterol (+70%), 2 surrogates of cholesterol absorption. In addition, atorvastatin significantly stimulated the intestinal expression of Niemann-Pick C1-Like 1 (+19%). 27 Altmann et al 28 has demonstrated that Niemann-Pick C1-Like 1 is critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte. These statin-mediated effects might upregulate the absorption of cholesterol, which potentially cause suboptimal lowering of LDL-C level in statin hyporesponders.
Many caveats should be noted with regard to the current analysis. The present findings result from the pooling of individual patient data from many clinical trials. Although these studies were similar in terms of patient populations, imaging acquisition, and core laboratory analysis, it is possible that there could be residual heterogeneous confounding factors, despite the use of mixed modeling statistical approaches to deal with pooling of the data. The current analysis includes intravascular ultrasound clinical trials, which tested nonstatin drugs (CAMELOT; placebo versus amlodipine versus enalapril, ACTIVATE; placebo versus pactimibe, ILLUSTRATE; atorvastatin only versus atorvastatin+torcetrapib, PERISCOPE; glimepiride versus pioglitazone, STRADIVARIUS; placebo versus rimonabant). [13] [14] [15] [16] [17] In particular, it might be concerned that pactimibe and torcetrapib have some effects on LDL-C level. However, different statin response in 2 groups was still observed in patients receiving pactimibe or torcetrapib (Tables  III and IV in the online-only Data Supplement). Although the current analysis reflects the relationship between hyporesponders to statin therapy and disease progression, resultant impact on clinical events remains to be determined. We have previously reported a direct relationship between atheroma progression and the occurrence of adverse cardiovascular events in patients with established coronary artery disease. Hence, greater atheroma progression in hyporesponders seems to potentially lead to the increased incidence of future cardiovascular events. 19 In summary, despite statins therapy, 20.0% of patients with coronary artery disease still harbored minimal reduction in LDL-C. In addition, hyporesponse to therapy is associated with rapidly progressive atherosclerotic forms. Our current study underscores monitoring LDL-C level after the commencement of statin to ensure adequate response to statin therapy. The current analysis also highlights clinical needs for emerging antiatherosclerotic therapies, which modify additional targets in statin hyporesponders.
